PMPRB Hearing Panel issues decision in Procysbi case

Patented Medicine Prices Review Board Canada

A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Pharma. The Panel has found that the price of Procysbi was and is excessive under section 83 and 85 of the Patent Act. The Panel has ordered Horizon to pay to His Majesty in right of Canada an amount calculated by the Parties and approved by the Panel. The Hearing Panel has also ordered Horizon to lower the price of Procysbi in Canada to no higher than the Maximum Potential Price prescribed by the Moderate Improvement Test applied by the Panel in its decision.

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.